Skip to main content

Author: Louise Stanley

High-profile appointee heightens ambition for Birmingham Health Partners

The second city’s strategic University-NHS alliance, Birmingham Health Partners (BHP) has announced the appointment of experienced business leader Jonathan Pearson as its new Chair, tasked with implementing an ambitious new strategy.

Bringing extensive experience as a management consultant and a profound understanding of the health and life sciences sector, Jonathan has established and guided numerous healthcare enterprises, spearheaded significant growth, and led large-scale transformation and technology programmes. He has also served within the NHS as Independent Chair of the Sandwell and West Birmingham Health System, bringing together a unique blend of high-level industry and health service expertise.

Jonathan’s contributions to the sector have earned him several prestigious accolades throughout his career. Notably, he was honoured with the Healthcare Deal of the Year award in 2014 by Acquisition International, recognised by the Management Consultancy Association in 2015 for thought leadership, and received the HSJ award for Analytic Provider of the Year in 2019. His exceptional leadership in the Sandwell ICP’s Covid vaccination program was further acknowledged with the Local Government Association award in 2021.

BHP is a strategic alliance uniting two renowned Universities, five NHS Trusts and Health Innovation West Midlands, with the shared aim of transforming healthcare across our region by leveraging collective strengths in clinical and technological innovation, research, and education.

Commenting on his appointment, Jonathan said: “Birmingham Health Partners is a powerhouse of research at the heart of an ambitious city and region, with a strong track record of scaling innovation from the bench to the bedside at pace. Together with its wider regional partners, BHP is already working to address pressing health challenges and deliver economic growth and this work will only be enhanced by the imminent launch of our new strategy which will benefit our communities, region and workforce. It is an incredibly exciting time to join the partnership.”

Spinal injury model funding awarded to BHP members

BHP members the Royal Orthopaedic Hospital and Aston University – working with the University of Edinburgh – have been awarded a joint research fellowship to develop a working 3D model of the spinal cord, to improve understanding of the management of compressive spinal cord pathology.

The fellowship is funded by Orthopaedic Research UK (ORUK), the British Association of Spine Surgeons (BASS) and the British Scoliosis Society (BSS) and the project will run for three years. The team is led by Professor Adrian Gardner – consultant spine surgeon at the Royal Orthopaedic Hospital and Jean-Baptiste Souppez – senior lecturer mechanical, biomedical and design engineering at Aston University. 

The idea for the project came about following a discussion between colleagues about a patient presenting with a multi-level degenerative cervical spine with multi-level spondylolisthesis. Multiple vertebra in the patient’s neck were compressing on each other and several of these vertebra were pushed forwards creating an unstable spine. 

Professor Gardner said: “I was able to make recommendations, however this was based on training over the years and experience. For example, there are multiple ways to approach this kind of injury – you could go in from the front (anterior) or the back (posterior), but the decision is largely down to how you’ve been trained.  It occurred to me that a physical model could be used to better understand the pathology and use scientific evidence to inform surgical solutions for our patients here at the Royal Orthopaedic Hospital and across the globe.”

Professor Gardner worked through potential options with contacts at Aston University, who recommended using 3D printing to simulate the different ways spinal cord compression happens, and its management. The model would be made up of a 3D printed, fully articulated vertebral column and use tuneable pneumatic pressure to replicate the spinal cord. Adjustable to reflect various spinal conditions, the model would enable spinal teams to test the likely impact of different procedures.

Degenerative Cervical Myelopathy (DCM) is one of the most common spinal injuries, caused by severe compression in the neck. This compression can come because of inflammation, arthritis and age. It can lead to issues with balance, dexterity and control of the bowel and bladder. If left untreated, myelopathy can lead to permanent spinal cord injury and nerve damage. 

Professor Gardner added: “Despite being common, DCMs are under researched. As spinal surgeons we often refer to it as a silent disease – studies show about 2% of the adult population have DCM, but the real number could be much higher. This is because patients may not be aware that they have a degenerative cervical myelopathy and will put their symptoms down to aging, never seeking out treatment. 

“With this fellowship we have the chance to enhance understanding of the best way to treat this under-researched condition and better support clinicians with their management plans. Timing is key in treating people with DCM to maximise recovery and outcomes, but surgeons have always been appropriately cautious due to the lack of research in this space. Ultimately, we hope that this model will help demonstrate that earlier intervention can prevent DCM becoming a serious disability.”

The project is supported by three students from the University of Aston who sit across different engineering disciplines: Design Engineering, Biomedical Engineering and Mechanical Engineering. 

Jean-Baptiste R. G. Souppez, senior lecturer in mechanical, biomedical and design engineering at Aston, co-lead on the project, commented: “The award of the inaugural ORUK/BASS/BSS fellowship has been instrumental in enabling this joint research project between the Royal Orthopaedic Hospital and Aston University’s Mechanical, Biomedical and Design Engineering department. 

“It is also fantastic to see the joint effort from three engineering disciplines, coming together to strengthen our commitment to our local community partners, developing innovative solutions to real-world problems as part of our Engineering for Health research centre at Aston University.” 

Our shared future – BHP publishes annual review of activity

Following a year in which Birmingham Health Partners expanded its membership to eight member organisations – welcoming Aston University and Birmingham and Solihull Mental Health NHS Foundation Trust – we’re pleased to publish our second annual review of activity for the period September 2022-August 2023. 

Download and read the Birmingham Health Partners Report of Activity 22-23  (PDF, 5MB)

Over the past year, BHP has demonstrated the benefits of collaboration across our organisations. The addition of new members and the emergence of integrated care systems together with changes in the funder landscape offer new opportunities for BHP to continue to develop and promote our collaborative purpose.

The year ahead will see us welcome a new Chair, new leaders at some of our Partner organisations and the publication of a strategic framework and delivery plan that reflects our ambitions for the region.

We have in our hands the tools that we need to succeed, the onus is on us to put them to work to ensure Birmingham is seen as the place where innovative research translates into improved health and economic growth.

Outgoing chair Ed Smith commented: “We were delighted to welcome Aston University and Birmingham and Solihull Mental Health NHS Foundation Trust to our membership during the year and now comprise two universities, five NHS Trusts, and the West Midlands AHSN. Our collaboration between such significant partners allows us to focus on research, innovation and health care capabilities to deal with important health issues in the region and indeed beyond through wider partnerships. 

“BHP’s key activities over the last year have been a focus on women’s health; improving the environment for clinical research fellowships; and our forward strategy for the next five years – which has been approved by the BHP Board and is focussed on delivering real value to the region from collaborative and skilled contributions which, in the prioritised areas, would be less effective than those from single organisations working individually.”

Downloads:

Birmingham Health Partners Report of Activity 22-23  (PDF, 5MB)
Birmingham Health Partners Report of Activity 2020 to 2022 pdf (4MB)

AI – safe and effective for everyone: new standards released by BHP members

An international initiative called STANDING Together – led by BHP founder-members University Hospitals Birmingham NHS Foundation Trust, and the University of Birmingham – has released new standards ensuring that medical artificial intelligence (AI) systems are developed with appropriate health datasets.

The STANDING Together recommendations ensure that the full diversity of people that AI systems will be used for, is represented in health datasets. This is imperative as AI systems are less likely to work well for people who aren’t properly represented in datasets – and may even be harmful. People who are in minority groups are particularly likely to be under-represented in datasets.

The recommendations provide guidance on collecting and reporting details such as age, sex, gender, race, ethnicity, and other important characteristics, and have been developed following a two-year research study involving over 350 people from 58 countries, including patients, researchers, healthcare professionals, industry experts, and regulators. They also recommend that any limitations of the dataset should be transparently reported to ensure that developers creating AI systems can choose the best data for their purpose. Guidance is also given on how to identify those who may be harmed when medical AI systems are used, allowing this risk to be reduced.

The research has been conducted with collaborators from over 30 institutions worldwide, including universities, the UK medicines regulator (the Medicines and Healthcare products Regulatory Agency, MHRA), patient groups and charities, and small and large health technology companies. The work has been funded by The Health Foundation and the NHS AI Lab and supported by the National Institute for Health and Care Research (NIHR).

Lead researcher Dr Xiaoxuan Liu, Clinical Scientist in AI and Digital Health Technologies at the University of Birmingham, explained: “AI models are underpinned by data, which captures a wealth of information. When dealing with health data, this information can unfortunately include existing health inequalities. These inequalities can come about in many ways, including underrepresentation of particular groups, or as a reflection of structural biases within wider society. It is vital that anyone using data to develop new innovations (including AI) are aware of any biases, and that they are accounted for. As we move towards an AI-enabled future, we can ensure these technologies don’t just work on average, but that they work for all.”

Dominic Cushnan, Director AI, Imaging & Deployment at the NHS AI Lab, said: “The lack of diversity and inclusivity in our current datasets are major challenges in our ability to ensure AI in health and care works for everyone. These standards are an important step towards transparent and common documentation of represented groups in our data, which can support the responsible and fair development and use of AI.”

The recommendations are available open access at www.datadiversity.org/recommendations to support the development of safe, effective and equitable AI tools for healthcare.

BHP members collaborate to explore tech, big data and AI in healthcare

Two members of Birmingham Health Partners – Aston University and Birmingham Women’s and Children’s NHS Foundation Trust (BWC) – are collaborating to explore how digital technology, big data and artificial intelligence can revolutionise healthcare.

To kick off the partnership, Aston University’s Engineering for Health Research Centre is co-hosting the BWC Innovation Summit, which brings together tech firms, healthcare professionals and academics to explore how new technology can benefit paediatric and women’s healthcare as well as the young people’s mental health sector.

Representatives from Hitachi, KPMG and the West Midlands Academic Health Science Network (WMAHSN) will be at the event on October 11th held at Conference Aston.

Amanda Baugh, Head of Innovation at BWC said: “The event is an opportunity to bring together professionals from different disciplines to foster collaboration and springboard ideas on the future of healthcare.

“We want to get a wide range of experts in one place to explore and define challenges and set out plans about how we can adapt and adopt existing technology, products and devices, along with how we might develop products and solutions not currently available to meet these challenges.”

Dr Antonio Fratini is head of Aston University’s Engineering for Health Research Centre. He said: “The University’s College of Engineering and Physical Sciences is delighted to be co-hosting this event which highlights Aston University’s mission to be a leading university of science, technology and enterprise.

“Through harnessing the power of medical and digital technology, analysis of big data and artificial intelligence we will be able to change healthcare – for example by providing care closer to home, improving access and therefore reducing inequalities.”

Stem cell therapy for heart attack patients trialled at UHB

A stem cell therapy trial at BHP founder-member University Hospitals Birmingham is having a life-changing effect on heart attack patients, with scans showing almost complete restoration of heart muscle function just weeks after the procedure. 

After a heart attack, around 30% of patients are left with severely damaged and weakened hearts which can, over time, lead to life-threatening heart failure, as the heart is unable to pump the blood around the body properly. The trial therapy aims to prevent this heart failure by regenerating the damaged muscle.

Developed by biotechnology company CellProthera, the therapy involves the application of a person’s own stem cells directly into their heart, through the femoral artery in the leg. The patient’s heart activity is then monitored for six months – at 1, 3 and 6 months – using echocardiography and magnetic resonance imaging (MRI).

66 year old Kim Smith is one of four patients recruited to the trial at UHB and was randomly allocated to the experimental arm of the study, meaning that she received the therapy as treatment following her heart attack. Just two weeks after receiving the therapy, Kim’s heart function had returned to almost normal (55%).

Kim said: “I now feel as though I can actually do what I used to do before. When I had the heart attack, I was worried that I was going to end up being stuck at home all day, but since having the stem cell therapy, psychologically and physically, I just feel so much better.

“I’m so grateful to have had this treatment, and I do hope that the research that they are doing goes forward because I think a lot of people would benefit. That was my reason for doing it in the first place – even if it does nothing for me, it could help someone else.”

So far, approximately 50 patients from the UK and France have been recruited to the trial, known as the EXCELLENT (Expanded Cell Endocardial Transplantation) study. The research is currently in its final phase, with results expected later this year.

Dr Sohail Khan, Consultant Interventional Cardiologist and Lead Investigator at UHB for the EXCELLENT study, said: “What we have seen so far is that actually the stem cells do seem to have a dramatic effect in terms of improving heart muscle function.

“Currently, there are few clinical options available that repair and regenerate heart tissue following a heart attack. As a result, the only option for many patients that have suffered a heart attack and developed advanced heart failure, is a fully invasive heart transplant. This is a very serious procedure for the patient, and very costly for society.

“The development of a cell therapy to regenerate cardiac tissue will be transformative for a considerable number of patients globally. A minimally invasive, cell therapy, that uses a patient’s own stem cells, could also considerably reduce treatment costs.”

Matthieu de Kalbermatten, CEO at CellProthera, said: “Bringing the therapy to market as a minimally invasive therapy is vital to tackle, from the root, the harmful effects of heart attacks and improve quality of so many lives.

“The impressive progress of the CellProthera EXCELLENT trial is a testament to the work of our team and our stakeholders. All of the trial sites in the UK and France are committed to admitting and treating the final patients as quickly as possible. In 2024, we will look to start the phase III trial, where we will be recruiting patients from across Europe, with the aim of potential future market authorisation and bringing this vital treatment to all patients.”